<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290029</url>
  </required_header>
  <id_info>
    <org_study_id>20090005</org_study_id>
    <nct_id>NCT01290029</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease</brief_title>
  <official_title>An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to evaluate the safety and tolerability of cinacalcet
      after a single oral dose in children aged 28 days to less than 6 years with chronic kidney
      disease receiving dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Day 1 to day 30</time_frame>
    <description>A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal • life threatening • requires in patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other medically important serious event. Treatment-related adverse events are those the investigator assessed as being possibly related to any study mandated activity (eg, administration of investigational product, protocol-required therapies, device(s) and/or procedure). Events of interest included acute pancreatitis, convulsions, drug related hepatic disorders, fractures, hypersensitivity, hypocalcemia, ischaemic heart disease, ventricular tachyarrhythmias, cardiac failure, and hypotension.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) for Cinacalcet</measure>
    <time_frame>Baseline (predose) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUCinf) for Cinacalcet</measure>
    <time_frame>Baseline (predose) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Cinacalcet</measure>
    <time_frame>Baseline (predose) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration of Cinacalcet (Tmax)</measure>
    <time_frame>Baseline (predose) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life of Cinacalcet</measure>
    <time_frame>Baseline (predose) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose</time_frame>
    <description>The terminal half-life (T1/2) of cinacalcet associated with the slope of the terminal phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Intact Parathyroid Hormone</measure>
    <time_frame>Baseline (predose) and at 2, 8, 12 and 48 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Calcium</measure>
    <time_frame>Baseline (predose) and 2, 8, 12 and 48 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Albumin Corrected Calcium</measure>
    <time_frame>Baseline (predose) and 2, 8, 12 and 48 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Ionized Calcium</measure>
    <time_frame>Baseline (predose) and 2, 8, 12 and 48 hours post-dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Hyperparathyroidism, Secondary</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Cinacalcet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single, oral dose of 0.25 mg/kg cinacalcet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cinacalcet</intervention_name>
    <description>Single, oral dose of 0.25 mg/kg cinacalcet</description>
    <arm_group_label>Cinacalcet</arm_group_label>
    <other_name>Sensipar®</other_name>
    <other_name>Mimpara®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject's parent, or legally acceptable guardian, must sign an Independent Ethics
             Committee (IEC) or Institutional Review Board (IRB) approved Informed Consent Form.

          -  Subjects 28 days to &lt; 6 years of age with chronic kidney disease (CKD) and secondary
             hyperparathyroidism (sHPT) as diagnosed by principal investigators, undergoing
             hemodialysis or peritoneal dialysis at the time of screening (subjects 6 months or
             older should have been receiving dialysis for ≥ 1 months) and who have not received
             any cinacalcet HCl therapy for at least 2 weeks prior to dosing on Day 1

          -  Free of any disease or condition (other than those diseases or conditions related to
             their renal disease that, in the opinion of the investigator, would impact the
             subject's safety or the integrity of the study data).

          -  Must weigh ≥ 6 kg at screening and at Day-1.

          -  Must be at least 30 weeks of gestational age.

          -  Physical examination must be acceptable to the investigator at screening and at Day
             -1.

          -  Hemoglobin ≥ 8 g/dL at screening and at Day -1.

          -  Serum calcium within age-appropriate normal ranges per the National Kidney Foundation
             Kidney Disease Outcomes Quality Initiative (NKF KDOQI) guidelines at screening and at
             Day -1

          -  Normal or clinically acceptable electrocardiogram (ECG) (12-lead reporting RR, PR,
             QRS, and QTc intervals) at screening and at Day -1.

          -  Clinical laboratory tests that are acceptable to the investigator at screening and at
             Day -1.

        Exclusion Criteria

          -  Current or historic malignancy.

          -  Cardiac ventricular arrhythmias within 28 days prior to screening.

          -  A gastrointestinal disorder or surgery that could affect the absorption of drugs (eg,
             pyloric stenosis or any gut-shortening surgical procedure prior to screening).

          -  A new onset of seizure or worsening of a pre-existing seizure disorder within 2 months
             prior to IP administration.

          -  Major surgery (defined as any surgical procedure that involves general anesthesia or
             respiratory assistance) within 28 days prior to screening.

          -  Hepatic impairment indicated by elevated levels of hepatic transaminase or bilirubin
             (aspartate aminotransferase (AST) ≥ 1.5 x upper limit of normal (ULN) OR alanine
             aminotransferase (ALT) ≥ 1.5 x ULN OR total bilirubin ≥ 1 x ULN per institutional
             laboratory range) at screening or Day-1.

          -  History of prolongation of the QT interval (eg, congenital long QT interval, second or
             third degree heart block or other conditions which prolong the QT interval)

          -  Corrected QT Interval (QTc) &gt; 500 ms during screening, using Bazett's formula

          -  QTc ≥ 450 and ≤ 500 ms during screening, using Bazett's formula, unless written
             permission to enroll is provided by the investigator after consultation with a
             pediatric cardiologist

          -  Known hypersensitivity to cinacalcet HCl or any of the excipients in cinacalcet HCl.

          -  Use of grapefruit juice, herbal medications or potent CYP 3A4 inhibitors (eg,
             erythromycin, clarithromycin, ketokonazole, itraconazole) within the 14 days prior to
             enrollment and during the study.

          -  Concurrent or within 28 days prior to enrollment use of medications that are
             predominantly metabolized by the enzyme CYP2D6 and have a narrow therapeutic index
             (eg, flecainide, vinblastine, thioridazine, tricyclic antidepressants such as
             desipramine and imipramine, and beta-blockers such as metoprolol or carvedilol).

          -  Concurrent or within 28 days prior to enrollment use of medications that prolong QT
             interval (eg, sotalol, amiodarone, erythromycin, or clarithromycin).

          -  Currently receiving treatment in another investigational device or drug study, or less
             than 90 days since ending treatment on another investigational device or drug
             study(s).

          -  Other investigational procedures while participating in this study are excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2190 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <results_first_submitted>August 9, 2016</results_first_submitted>
  <results_first_submitted_qc>October 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2016</results_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>CKD</keyword>
  <keyword>dialysis</keyword>
  <keyword>paediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cinacalcet Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 7 study centers in Belgium (1 site), Germany (1 site), the United Kingdom (2 sites), and the United States (3 sites). The first participant was enrolled 25 January 2011 and the last participant on 25 August 2015.</recruitment_details>
      <pre_assignment_details>Due to blood volume collection limitations in children, participants were randomized in a 1:1 ratio to one of the following 2 pharmacodynamic (PD) sampling sequences: 2, 8, and 48 hours postdose; or 2, 12, and 48 hours postdose.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cinacalcet 0.25 mg/kg</title>
          <description>Participants were to receive a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants</population>
      <group_list>
        <group group_id="B1">
          <title>Cinacalcet 0.25 mg/kg</title>
          <description>Participants were to receive a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black (or African American)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal • life threatening • requires in patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other medically important serious event. Treatment-related adverse events are those the investigator assessed as being possibly related to any study mandated activity (eg, administration of investigational product, protocol-required therapies, device(s) and/or procedure). Events of interest included acute pancreatitis, convulsions, drug related hepatic disorders, fractures, hypersensitivity, hypocalcemia, ischaemic heart disease, ventricular tachyarrhythmias, cardiac failure, and hypotension.</description>
        <time_frame>Day 1 to day 30</time_frame>
        <population>All participants who received at least 1 dose of cinacalcet.</population>
        <group_list>
          <group group_id="O1">
            <title>Cinacalcet 0.25 mg/kg</title>
            <description>Participants received a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal • life threatening • requires in patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other medically important serious event. Treatment-related adverse events are those the investigator assessed as being possibly related to any study mandated activity (eg, administration of investigational product, protocol-required therapies, device(s) and/or procedure). Events of interest included acute pancreatitis, convulsions, drug related hepatic disorders, fractures, hypersensitivity, hypocalcemia, ischaemic heart disease, ventricular tachyarrhythmias, cardiac failure, and hypotension.</description>
          <population>All participants who received at least 1 dose of cinacalcet.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events of interest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) for Cinacalcet</title>
        <time_frame>Baseline (predose) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose</time_frame>
        <population>Pharmacokinetics analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Cinacalcet 0.25 mg/kg</title>
            <description>Participants received a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) for Cinacalcet</title>
          <population>Pharmacokinetics analysis set</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="8.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUCinf) for Cinacalcet</title>
        <time_frame>Baseline (predose) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose</time_frame>
        <population>Pharmacokinetics analysis set; The AUCinf value for one participant was excluded based on the goodness-of-fit (R²) value exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Cinacalcet 0.25 mg/kg</title>
            <description>Participants received a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUCinf) for Cinacalcet</title>
          <population>Pharmacokinetics analysis set; The AUCinf value for one participant was excluded based on the goodness-of-fit (R²) value exclusion criteria.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Cinacalcet</title>
        <time_frame>Baseline (predose) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose</time_frame>
        <population>Pharmacokinetics analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Cinacalcet 0.25 mg/kg</title>
            <description>Participants received a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Cinacalcet</title>
          <population>Pharmacokinetics analysis set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration of Cinacalcet (Tmax)</title>
        <time_frame>Baseline (predose) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose</time_frame>
        <population>Pharmacokinetics analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Cinacalcet 0.25 mg/kg</title>
            <description>Participants received a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration of Cinacalcet (Tmax)</title>
          <population>Pharmacokinetics analysis set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.820" lower_limit="0.50" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life of Cinacalcet</title>
        <description>The terminal half-life (T1/2) of cinacalcet associated with the slope of the terminal phase.</description>
        <time_frame>Baseline (predose) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose</time_frame>
        <population>Pharmacokinetics analysis set; The T1/2 value for one participant was excluded based on the goodness-of-fit (R²) value exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Cinacalcet 0.25 mg/kg</title>
            <description>Participants received a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life of Cinacalcet</title>
          <description>The terminal half-life (T1/2) of cinacalcet associated with the slope of the terminal phase.</description>
          <population>Pharmacokinetics analysis set; The T1/2 value for one participant was excluded based on the goodness-of-fit (R²) value exclusion criteria.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Intact Parathyroid Hormone</title>
        <time_frame>Baseline (predose) and at 2, 8, 12 and 48 hours post-dose.</time_frame>
        <population>Due to the randomization to 1 of 2 sampling sequences not all participants had PD samples taken at every time point. &quot;n&quot; indicates participants with non-missing data at the time point of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Cinacalcet 0.25 mg/kg</title>
            <description>Participants received a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Intact Parathyroid Hormone</title>
          <population>Due to the randomization to 1 of 2 sampling sequences not all participants had PD samples taken at every time point. &quot;n&quot; indicates participants with non-missing data at the time point of interest.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours post-dose (n = 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.80" lower_limit="-18.50" upper_limit="23.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose (n = 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.6" lower_limit="-42.20" upper_limit="-12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose (n = 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.40" lower_limit="27.70" upper_limit="31.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-dose (n = 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.40" lower_limit="-42.30" upper_limit="69.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Calcium</title>
        <time_frame>Baseline (predose) and 2, 8, 12 and 48 hours post-dose.</time_frame>
        <population>Due to the randomization to 1 of 2 sampling sequences not all participants had PD samples taken at every time point. &quot;n&quot; indicates participants with non-missing data at the time point of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Cinacalcet 0.25 mg/kg</title>
            <description>Participants received a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Calcium</title>
          <population>Due to the randomization to 1 of 2 sampling sequences not all participants had PD samples taken at every time point. &quot;n&quot; indicates participants with non-missing data at the time point of interest.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours post-dose (n = 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.33" spread="6.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose (n = 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.38" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose (n = 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.63" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-dose (n = 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.54" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Albumin Corrected Calcium</title>
        <time_frame>Baseline (predose) and 2, 8, 12 and 48 hours post-dose.</time_frame>
        <population>Due to the randomization to 1 of 2 sampling sequences not all participants had PD samples taken at every time point. &quot;n&quot; indicates participants with non-missing data at the time point of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Cinacalcet 0.25 mg/kg</title>
            <description>Participants received a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Albumin Corrected Calcium</title>
          <population>Due to the randomization to 1 of 2 sampling sequences not all participants had PD samples taken at every time point. &quot;n&quot; indicates participants with non-missing data at the time point of interest.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours post-dose (n = 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.01" spread="7.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose (n = 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.12" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose (n = 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.24" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-dose (n = 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Ionized Calcium</title>
        <time_frame>Baseline (predose) and 2, 8, 12 and 48 hours post-dose.</time_frame>
        <population>Due to the randomization to 1 of 2 sampling sequences not all participants had PD samples taken at every time point. &quot;n&quot; indicates participants with non-missing data at the time point of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Cinacalcet 0.25 mg/kg</title>
            <description>Participants received a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Ionized Calcium</title>
          <population>Due to the randomization to 1 of 2 sampling sequences not all participants had PD samples taken at every time point. &quot;n&quot; indicates participants with non-missing data at the time point of interest.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours post-dose (n = 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose (n = 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.20" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose (n = 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.15" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-dose (n = 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 Days</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cinacalcet 0.25 mg/kg</title>
          <description>Participants received a single oral dose of 0.25 mg/kg cinacalcet on day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Device expulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

